- Home
- ONDS vs SGMT Comparison
ONDS vs SGMT Comparison
Compare ONDS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- SGMT
- Stock Information
- Founded
- ONDS 2014
- SGMT 2006
- Country
- ONDS United States
- SGMT United States
- Employees
- ONDS N/A
- SGMT N/A
- Industry
- ONDS Telecommunications Equipment
- SGMT
- Sector
- ONDS Telecommunications
- SGMT
- Exchange
- ONDS Nasdaq
- SGMT Nasdaq
- Market Cap
- ONDS 108.4M
- SGMT 128.5M
- IPO Year
- ONDS N/A
- SGMT 2023
- Fundamental
- Price
- ONDS $1.10
- SGMT $2.58
- Analyst Decision
- ONDS Buy
- SGMT Strong Buy
- Analyst Count
- ONDS 1
- SGMT 6
- Target Price
- ONDS $4.00
- SGMT $25.67
- AVG Volume (30 Days)
- ONDS 12.3M
- SGMT 333.5K
- Earning Date
- ONDS 03-12-2025
- SGMT 03-12-2025
- Dividend Yield
- ONDS N/A
- SGMT N/A
- EPS Growth
- ONDS N/A
- SGMT N/A
- EPS
- ONDS N/A
- SGMT N/A
- Revenue
- ONDS $7,192,694.00
- SGMT N/A
- Revenue This Year
- ONDS $374.26
- SGMT N/A
- Revenue Next Year
- ONDS $94.33
- SGMT N/A
- P/E Ratio
- ONDS N/A
- SGMT N/A
- Revenue Growth
- ONDS N/A
- SGMT N/A
- 52 Week Low
- ONDS $0.54
- SGMT $2.39
- 52 Week High
- ONDS $3.40
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- ONDS 55.41
- SGMT 25.28
- Support Level
- ONDS $0.72
- SGMT $3.89
- Resistance Level
- ONDS $1.25
- SGMT $4.24
- Average True Range (ATR)
- ONDS 0.13
- SGMT 0.29
- MACD
- ONDS 0.08
- SGMT -0.08
- Stochastic Oscillator
- ONDS 75.00
- SGMT 3.49
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.